Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
| Autor: | Pietro Lampertico, Heiner Wedemeyer, Marcello Persico, Fiona Marra, Kristina Lohmann, Steven L. Flamm, Mark Bondin, Steven E Marx, Stephen T. Barclay, Zhen Zhen Zhang, Pamela S. Belperio, Stefan Mauss |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
030213 general clinical medicine
medicine.medical_specialty Cirrhosis Population Medizin Review Therapeutics 03 medical and health sciences Underserved Population 0302 clinical medicine Internal medicine Medicine Pharmacology (medical) education education.field_of_study Infectious disease business.industry Brief Report General Medicine Glecaprevir Hepatitis C medicine.disease Fibrosis Pibrentasvir Clinical trial Regimen 030220 oncology & carcinogenesis business |
| Zdroj: | Advances in Therapy ADVANCES IN THERAPY |
| ISSN: | 1865-8652 0741-238X |
| Popis: | Introduction: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosis in Europe and the USA, who would previously have received glecaprevir/pibrentasvir for 12 weeks. This label update was based on the EXPEDITION-8 study, which included 343 treatment-naïve patients with compensated cirrhosis. However, there is currently a lack of similarly large-scale real-world studies of the 8-week glecaprevir/pibrentasvir regimen in this population. Methods: This summary of seven separate smaller real-world studies aims to validate the results seen in EXPEDITION-8 and provide an up-to-date real-world reference for clinicians making treatment decisions for patients with compensated cirrhosis (Child–Pugh A) who may benefit from a shorter-duration therapy with glecaprevir/pibrentasvir. The newly emerging real-world effectiveness data on treatment-naïve patients with compensated cirrhosis treated with 8 weeks of glecaprevir/pibrentasvir help to understand where further research is needed to support patients with hepatitis C virus. Results: Across all seven studies, glecaprevir/pibrentasvir showed high effectiveness with an average sustained virologic response rate of 98.1%, similar to that found in a clinical trial setting (99.7%). Only one patient (0.5%) experienced virologic failure and treatment was well tolerated. Conclusion: Expanding the number of patients eligible for the shortened treatment duration will potentially increase treatment initiation and completion, particularly in underserved populations, contributing to the elimination of hepatitis C virus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink